Source: http://www.google.com/patents/US4603106?dq=7,550,386
Timestamp: 2017-03-27 15:43:21
Document Index: 787839543

Matched Legal Cases: ['art 1', 'art 1', 'art 1', 'art 1', 'art 1', 'art 2', 'art 2', 'art 1']

Patent US4603106 - Lipoprotein lipase suppression by endotoxin-induced mediator (shock assay) - Google PatentsSearch Images Maps Play YouTube News Gmail Drive More »Sign inPatentsA mediator substance exhibiting inhibitory effect upon anabolic enzyme activity in mammals, is prepared by a method comprising gathering a sample of macrophage cells from a mammal, incubating a portion of the macrophage cells with a stimulating material that is associated with an invasive event, and...http://www.google.com/patents/US4603106?utm_source=gb-gplus-sharePatent US4603106 - Lipoprotein lipase suppression by endotoxin-induced mediator (shock assay)Advanced Patent SearchTry the new Google Patents, with machine-classified Google Scholar results, and Japanese and South Korean patents.Publication numberUS4603106 APublication typeGrantApplication numberUS 06/414,098Publication dateJul 29, 1986Filing dateSep 7, 1982Priority dateFeb 22, 1982Fee statusPaidPublication number06414098, 414098, US 4603106 A, US 4603106A, US-A-4603106, US4603106 A, US4603106AInventorsAnthony Cerami, Masanobu KawakamiOriginal AssigneeThe Rockefeller UniversityExport CitationBiBTeX, EndNote, RefManPatent Citations (2), Non-Patent Citations (158), Referenced by (182), Classifications (53), Legal Events (4) External Links: USPTO, USPTO Assignment, EspacenetLipoprotein lipase suppression by endotoxin-induced mediator (shock assay)
______________________________________Cell number    3.0 (× 10-6 /ml)ALA dehydratase          3.00 (nmol PBG/106 cells, h)PBG deaminase  120 (pmol uroporphyrinogen/106          cells, h)Protoporphyrin 0.57 (pmol/106 cells)Heme           520 (pmol/106 cells)______________________________________
Patent CitationsCited PatentFiling datePublication dateApplicantTitleUS29169 *Jul 17, 1860 Improvement in gang-plowsUS4242322 *Jun 7, 1978Dec 30, 1980Electro-Nucleonics Laboratories, Inc.Methods and materials for detecting antigens and antibodies* Cited by examinerNon-Patent CitationsReference1 *Atkins, P. C., et al., J. Allergy Clin. Immunol. (JACIB), 64(4), pp. 251 258, (1979).2Atkins, P. C., et al., J. Allergy Clin. Immunol. (JACIB), 64(4), pp. 251-258, (1979).3 *B. Beutler, et al., Journal of Experimental Medicine, at vol. 161, pp. 984 995 (May, 1985, The Rockefeller University Press).4B. Beutler, et al., Journal of Experimental Medicine, at vol. 161, pp. 984-995 (May, 1985, The Rockefeller University Press).5 *Bagby, G. J., et al., Am. J. Physiol. 238, pp. 325 330, (1980).6Bagby, G. J., et al., Am. J. Physiol. 238, pp. 325-330, (1980).7 *Barclay, M., et al., Prog. Biochem. Pharmacol. 10, 76 111, (1975).8Barclay, M., et al., Prog. Biochem. Pharmacol. 10, 76-111, (1975).9 *Barney, C. C., et al., Lipton, J. M., (ed.), Fever: International Symposium, Dallas, Texas, USA, Apr. 11 12, 1979, XII 263P. Raven Press: New York, Illus. ISBN 0 89004 451 1, (08877), 0(0), pp. 111 122, (1980).10Barney, C. C., et al., Lipton, J. M., (ed.), Fever: International Symposium, Dallas, Texas, USA, Apr. 11-12, 1979, XII+263P. Raven Press: New York, Illus. ISBN 0-89004-451-1, (08877), 0(0), pp. 111-122, (1980).11 *Beisel, W. R., Ann. Rev. Med., 26:9 20 (1975).12Beisel, W. R., Ann. Rev. Med., 26:9-20 (1975).13 *Bornstein, D. L., et al., 38th. Annual National Meeting of the American Federation for Clinical Research, San Francisco, California, USA., Apr. 25 27, 1981, Clin. Res. (CLREA), 29(2), p. 381A, (1981).14Bornstein, D. L., et al., 38th. Annual National Meeting of the American Federation for Clinical Research, San Francisco, California, USA., Apr. 25-27, 1981, Clin. Res. (CLREA), 29(2), p. 381A, (1981).15 *Brenneman, D. E., et al., Eur. J. Cancer 11, 225 230, (1975).16Brenneman, D. E., et al., Eur. J. Cancer 11, 225-230, (1975).17 *Cameron, D. J., et al., J. Clin. Invest. (JCINA), 63(5), pp. 977 984, (1979).18Cameron, D. J., et al., J. Clin. Invest. (JCINA), 63(5), pp. 977-984, (1979).19 *Carey, F. J., et al., J. Clin. Invest. 37:441, (1958).20 *Carr, B. R., et al., J. Clin. Endocrinol. Metab. (JCEMA), 52(6), pp. 1124 1128, (1981).21Carr, B. R., et al., J. Clin. Endocrinol. Metab. (JCEMA), 52(6), pp. 1124-1128, (1981).22 *Chang, T Y, et al., J. Biol. Chem. (JBCHA) 256(12), pp. 6174 6180, (1981).23Chang, T-Y, et al., J. Biol. Chem. (JBCHA) 256(12), pp. 6174-6180, (1981).24 *Charles A. Dinarello, Reviews of Infectious Diseases, at vol. 6, No. 1, (Jan. Feb. 1984).25Charles A. Dinarello, Reviews of Infectious Diseases, at vol. 6, No. 1, (Jan.-Feb. 1984).26 *Chaudry, I. H., et al., Arch. Surg. 109, 412 415, (1978).27Chaudry, I. H., et al., Arch. Surg. 109, 412-415, (1978).28 *Cohen, S., Am. J. Pathol. (AJPAA), 88(3), pp. 502 528, (1977).29Cohen, S., Am. J. Pathol. (AJPAA), 88(3), pp. 502-528, (1977).30 *Coleman, R. A., et al., J. Biol. Chem. 253, 7256 7261, (1978).31Coleman, R. A., et al., J. Biol. Chem. 253, 7256-7261, (1978).32Dinarello et al, "Human Leukocytic Pyrogen: Purification and Development of a Radioimmunoassay", Proceedings of the National Academy of Sciences, 74(10), p. 4624 (1977).33 *Dinarello et al, Human Leukocytic Pyrogen: Purification and Development of a Radioimmunoassay , Proceedings of the National Academy of Sciences, 74(10), p. 4624 (1977).34 *Dinarello, C. A., Fed. Proc. 38:52 56 (1979).35Dinarello, C. A., Fed. Proc. 38:52-56 (1979).36 *Eckel, R. H. et al., Biochem. Biophys, Res. Commun. 78, 288 293, (1977).37Eckel, R. H. et al., Biochem. Biophys, Res. Commun. 78, 288-293, (1977).38 *Eckel, R. H., et al., Biochem. Biophys. Res. Commun. 84, 1069 1075, (1978).39Eckel, R. H., et al., Biochem. Biophys. Res. Commun. 84, 1069-1075, (1978).40 *Edelson, P. J., et al. J. Exp. Med. 142, 1150 1164, (1975).41Edelson, P. J., et al. J. Exp. Med. 142, 1150-1164, (1975).42 *Farshtchi, D. et al., J. Bacteriol. 95:1615, (1968).43 *Fielding, C. J., et al., Arch. Pathol. Lab. Med. 101:225, (1977).44 *Fischer, C. L., et al., II: Serum Protein Abnormalities: Diagnostic and Clinical Aspects, eds. Ritzman, S. E. & Daniels, J. C. (Little Brown, Boston), pp. 331 350, (1975).45Fischer, C. L., et al., II: Serum Protein Abnormalities: Diagnostic and Clinical Aspects, eds. Ritzman, S. E. & Daniels, J. C. (Little Brown, Boston), pp. 331-350, (1975).46 *Frayn, K. N., Europ. J. Clin. Invest. 5:331 337 (1975).47Frayn, K. N., Europ. J. Clin. Invest. 5:331-337 (1975).48 *Gallin, E. K. et al., Cell Immunol. (CLIMB) 27(2) at 348, (1976).49 *Gallin, J. I., et al., N. Engl. J. Med. 281:1081, (1969).50 *Green, H., et al., Cell 1, 113 116, (1974).51Green, H., et al., Cell 1, 113-116, (1974).52 *Green, H., et al., Cell 5, 19 27, (1975).53Green, H., et al., Cell 5, 19-27, (1975).54 *Green, H., et al., Cell 7, 105 113, (1976).55Green, H., et al., Cell 7, 105-113, (1976).56 *Grossberg, S. E., et al., Nature (London), 208:954, (1965).57 *Havel, R. J., et al., J. Clin. Invest. 39:1777, (1960).58 *Herring, W. B., et al., J. Clin. Invest. 42:79, (1963).59 *Hirsh, R. L., McKay, D. G., Travers, R. I., and Skraly, R. K., J. LIPID Res., 5:563 568 (1964).60Hirsh, R. L., McKay, D. G., Travers, R. I., and Skraly, R. K., J. LIPID Res., 5:563-568 (1964).61 *Hoffman Goetz, L. et al., Am. J. Clin. Nutr. (AJCNA), 32(7), pp. 1423 1427, (1979).62Hoffman-Goetz, L. et al., Am. J. Clin. Nutr. (AJCNA), 32(7), pp. 1423-1427, (1979).63 *Itkin, I. H., et al., J. Allergy (JOALA), 41(2), pp. 88 89, (1968).64Itkin, I. H., et al., J. Allergy (JOALA), 41(2), pp. 88-89, (1968).65 *Johnson, H. M., et al., Cell Immunol. (CLIMB), 44(1), pp. 125 130, (1979).66Johnson, H. M., et al., Cell Immunol. (CLIMB), 44(1), pp. 125-130, (1979).67 *Johnson, H. M., et al., IRCS (Int. Res. Commun. Syst.) Med. Sci. Libr. Compend. (IRLCA), 4 (5) p. 187 (1976).68 *Juniper, E. F., et al., Clin. Allergy (CLAGB), 11(1), pp. 61 66, (1981).69Juniper, E. F., et al., Clin. Allergy (CLAGB), 11(1), pp. 61-66, (1981).70 *Kaliner, M., Am. Rev. Respir. Dis (ARDSB), 118(6 Part 1), (Received 1979), pp. 1015 1022, (1978).71Kaliner, M., Am. Rev. Respir. Dis (ARDSB), 118(6 Part 1), (Received 1979), pp. 1015-1022, (1978).72 *Kampschmidt, R. F., Ann. Okla, Acad. Sci. (AOASA), 4, pp. 62 67 (1974).73Kampschmidt, R. F., Ann. Okla, Acad. Sci. (AOASA), 4, pp. 62-67 (1974).74 *Kampschmidt, R. F., et al., J. Lab. Clin. Med., 95:616 623, (1980).75Kampschmidt, R. F., et al., J. Lab. Clin. Med., 95:616-623, (1980).76 *Kampschmidt, R. F., et al., J. Reticuloendothel, Soc. (RESJA), 28(2), pp. 191 201, (1980).77Kampschmidt, R. F., et al., J. Reticuloendothel, Soc. (RESJA), 28(2), pp. 191-201, (1980).78 *Kampschmidt, R. F., J. Reticuloendothel. Soc., 23:287 297 (1978).79Kampschmidt, R. F., J. Reticuloendothel. Soc., 23:287-297 (1978).80 *Kampschmidt, R. F., Lipton, J. M., (ed.), Fever: International Symposium, Dallas, Texas, USA, Apr. 11 12, 1979, XII 263P. Raven Press: New York, USA. Illus., ISBN 0 89004 451 1, (08877) 0(0), pp. 49 56, (1980).81Kampschmidt, R. F., Lipton, J. M., (ed.), Fever: International Symposium, Dallas, Texas, USA, Apr. 11-12, 1979, XII+263P. Raven Press: New York, USA. Illus., ISBN 0-89004-451-1, (08877) 0(0), pp. 49-56, (1980).82 *Kawakami, M., et al., J. Exp. Med. 154, 631 639, (1981).83Kawakami, M., et al., J. Exp. Med. 154, 631-639, (1981).84 *Keenan, R. A., et al., 65th. Annual Meeting of the Federation of American Societies for Experimental Biology, Atlanta, Ga., USA., Apr. 12 17, 1981, Fed. Proc. (FEPRA), 40(3 Part 1), p. 439, (1981).85Keenan, R. A., et al., 65th. Annual Meeting of the Federation of American Societies for Experimental Biology, Atlanta, Ga., USA., Apr. 12-17, 1981, Fed. Proc. (FEPRA), 40(3 Part 1), p. 439, (1981).86 *Kempf, K. E., et al., J. Immunol. (JOIMA), 119(2), pp. 517 523, (1977).87Kempf, K. E., et al., J. Immunol. (JOIMA), 119(2), pp. 517-523, (1977).88 *Kennerly, D. A., et al., J. Immunol. (JOIMA), 122 (1), pp. 152 159 (1979).89Kennerly, D. A., et al., J. Immunol. (JOIMA), 122 (1), pp. 152-159 (1979).90 *Korn, E. D., J. Biol. Chem. 215, 1 14, (1955).91Korn, E. D., J. Biol. Chem. 215, 1-14, (1955).92 *Korn, E. D., J. Biol. Chem. 215, 15 26, (1955).93Korn, E. D., J. Biol. Chem. 215, 15-26, (1955).94 *Krejci, J., et al., Folia. Microbiol. (FOMIA) 13(6), p. 562, (1968).95 *Mackall, J. C., et al., J. Biol. Chem. 251, 6462 6464, (1976).96Mackall, J. C., et al., J. Biol. Chem. 251, 6462-6464, (1976).97 *Mapes, C. A., et al., Fed. Proc. (FEPRA) 36 (3) p. 1138 (1977).98 *McAdam, K. P. W. J., et al., Lancet II:572, (1975).99 *Merriman, C. R., et al., Proc. Soc. Exp. Biol. Med. (PSEBA), 154 (2) pp. 224 227 (1977).100Merriman, C. R., et al., Proc. Soc. Exp. Biol. Med. (PSEBA), 154 (2) pp. 224-227 (1977).101 *Michalek, S. M., et al., Fed. Proc. (FEPRA), 38(3 Part 1), 1284, (1979).102 *Newborg, M. F., et al., Infec. Immun. (INFIB), 24 (3) pp. 667 672 (1979).103Newborg, M. F., et al., Infec. Immun. (INFIB), 24 (3) pp. 667-672 (1979).104 *Nilsson Ehle, P., et al., J. Lipid Res. 17, 536 541, (1976).105Nilsson-Ehle, P., et al., J. Lipid Res. 17, 536-541, (1976).106 *Okpako, D. T., Int. Arch. Allergy Appl. Immunol. (IAAAA) 40(4 5), pp. 620 630, (1971).107Okpako, D. T., Int. Arch. Allergy Appl. Immunol. (IAAAA) 40(4-5), pp. 620-630, (1971).108 *Olivecroma, T., et al., Fed. Proc. Fed. Am. Soc. Exp. Biol. 36, 60 65.109Olivecroma, T., et al., Fed. Proc. Fed. Am. Soc. Exp. Biol. 36, 60-65.110 *Paterson, N. A. M. et al., Pneumonologie (PNMGA), 153 (2) p. 148 (1976).111 *Paterson, N. A. M., et al., Fed. Proc. (FEPRA), 35 (3) p. 865 (1976).112 *Peterson, C. M. et al., Diabetes, 26:507 509 (1977).113Peterson, C. M. et al., Diabetes, 26:507-509 (1977).114 *Plescia, O. J., Cell Immunol. (CLIMB) 27(2) at 348 349 (1976).115Plescia, O. J., Cell Immunol. (CLIMB) 27(2) at 348-349 (1976).116 *Pyk list , O. J., et al., (1975), Proc. Soc. Exp. Biol. Med. 148:297, (1975).117 *Pyk list , O. J., et al., J. Clin. Invest. 56:1108, (1975).118Pykalisto, O. J., et al., (1975), Proc. Soc. Exp. Biol. Med. 148:297, (1975).119Pykalisto, O. J., et al., J. Clin. Invest. 56:1108, (1975).120 *Rosenthal, C. J., et al., J. Clin. Invest. 55:746, (1975).121 *Rouzer, C. A. et al., Mol. Biochem. Parasitol. 2, 31 38, (1980).122Rouzer, C. A. et al., Mol. Biochem. Parasitol. 2, 31-38, (1980).123 *Rubin, C. S., et al., J. Biol. Chem. 253, 7570 7578, (1978).124Rubin, C. S., et al., J. Biol. Chem. 253, 7570-7578, (1978).125 *Sakaguchi, O., and Sakaguchi, S., Microbiol. Immunol. 23:71 85. (1979).126Sakaguchi, O., and Sakaguchi, S., Microbiol. Immunol. 23:71-85. (1979).127 *Selvam, R. et al., Indian J. Biochem. Biophys. (IJBBB), 15(2) pp. 115 121, (1978).128Selvam, R. et al., Indian J. Biochem. Biophys. (IJBBB), 15(2) pp. 115-121, (1978).129 *Sethi, K. K., et al., Arch. Virol. (ARVID), 59(3), pp. 157 172, (1979).130Sethi, K. K., et al., Arch. Virol. (ARVID), 59(3), pp. 157-172, (1979).131 *Shaw, G. M., et al., Cell Immunol. (CLIMB), 41(1), pp. 122 133, (1978).132Shaw, G. M., et al., Cell Immunol. (CLIMB), 41(1), pp. 122-133, (1978).133 *Sipe, J. D., et al., J. Exp. Med. 150, 597 606, (1979).134Sipe, J. D., et al., J. Exp. Med. 150, 597-606, (1979).135 *Skarnes, R. C., et al., J. Exp. Med. (JEMEA) 154(4), pp. 1212 1224, (1981).136Skarnes, R. C., et al., J. Exp. Med. (JEMEA) 154(4), pp. 1212-1224, (1981).137 *Spooner, P. M., et al., J. Biol. Chem. 254, 10021 10029, (1979).138Spooner, P. M., et al., J. Biol. Chem. 254, 10021-10029, (1979).139 *Spooner, P. M., et al., J. Biol. Chem. 254, 1305 1311, (1979).140Spooner, P. M., et al., J. Biol. Chem. 254, 1305-1311, (1979).141 *Student, A. K., et al., J. Biol. Chem. 255, 4745 4750, (1980).142Student, A. K., et al., J. Biol. Chem. 255, 4745-4750, (1980).143 *Sultzer, B. M. Nature (London), 219:1253, (1968).144 *Taskinen, M., et al., Diabetologia 17:351, (1979).145 *Wannemacher, R. W., Jr., et al., Infect. Immun. (INFIB) 11 (4) pp. 873 875 (1975).146Wannemacher, R. W., Jr., et al., Infect. Immun. (INFIB) 11 (4) pp. 873-875 (1975).147 *Wardley, R. C., et al., Res. J. Reticuloendothel. Soc. (RESJA), 19 (5) pp. 323 332 (1976).148Wardley, R. C., et al., Res. J. Reticuloendothel. Soc. (RESJA), 19 (5) pp. 323-332 (1976).149 *Wecker, E., et al., Ann. N.Y. Acad. Sci. (ANYAA) 249, pp. 258 263 (1975).150Wecker, E., et al., Ann. N.Y. Acad. Sci. (ANYAA) 249, pp. 258-263 (1975).151 *Werner, M., Clin. Chem. Acta. 25:299, (1969).152 *Westphal, O., et al., in Method in Carbohydrate Chemistry, eds. Whistler, R. L. BeMiller, J. N. & Wolfrom, M. L., Academic, New York, vol. 5, pp. 83 91, (1965).153Westphal, O., et al., in Method in Carbohydrate Chemistry, eds. Whistler, R. L. BeMiller, J. N. & Wolfrom, M. L., Academic, New York, vol. 5, pp. 83-91, (1965).154 *Wise, L. S., et al., Cell 13, 233 242, (1978).155Wise, L. S., et al., Cell 13, 233-242, (1978).156 *Yang, R. D., et al., 65th. Annual Meeting of the Federation of American Societies for Experimental Biology, Atlanta, Georgia, USA., Apr. 12 17, 1981, Fed. Proc. (FEPRA), 40(3 Part 2), p. 901, (1981).157Yang, R. D., et al., 65th. Annual Meeting of the Federation of American Societies for Experimental Biology, Atlanta, Georgia, USA., Apr. 12-17, 1981, Fed. Proc. (FEPRA), 40(3 Part 2), p. 901, (1981).158 *Zubler, R. H., et al., Fed. Proc. (FEPRA), 38(3 Part 1), 1276, (1979).* Cited by examinerReferenced byCiting PatentFiling datePublication dateApplicantTitleUS5106520 *Jan 9, 1990Apr 21, 1992The University Of DaytonDry powder mixes comprising phase change materialsUS5137805 *Jan 25, 1989Aug 11, 1992The General Hospital CorporationMethod of diagnosing stress condition by specific binding of human heat shock factorUS5145676 *Feb 7, 1991Sep 8, 1992The Rockefeller UniversityMethod and agents for promoting wound healingUS5364793 *Dec 1, 1992Nov 15, 1994Monoclonetics International, Inc.Methods for the diagnosis of peripheral nerve damageUS5436154 *Dec 13, 1991Jul 25, 1995Farmitalia Carlo Erba S.R.L.Monoclonal antibodies against human Tumor Necrosis Factor αUS5477917 *Sep 29, 1994Dec 26, 1995The University Of DaytonDry powder mixes comprising phase change materialsUS5583201 *May 16, 1994Dec 10, 1996Monoclonetics International, Inc.Methods for diagnosis of peripheral nerve damageUS5591827 *Dec 16, 1994Jan 7, 1997Cetus Oncology CorporationInterleukin-6 receptor antagonistsUS5616688 *Mar 7, 1994Apr 1, 1997The Rockefeller UniversityMacrophage-derived inflammatory mediator (MIP-1α and MIP-1β)US5650147 *Mar 7, 1994Jul 22, 1997The Rockefeller UniversityMethods of stimulating granulocyte-macrophage progenitor cellsUS5656272 *Feb 4, 1994Aug 12, 1997New York University Medical CenterMethods of treating TNF-α-mediated Crohn's disease using chimeric anti-TNF antibodiesUS5658803 *Dec 6, 1994Aug 19, 1997Chiron CorporationMonoclonal antibodies reactive with cachectinUS5698195 *Oct 18, 1994Dec 16, 1997New York University Medical CenterMethods of treating rheumatoid arthritis using chimeric anti-TNF antibodiesUS5703206 *Aug 3, 1994Dec 30, 1997Univ RockefellerMacrophage inflammatory protein 2 (MIP-2)US5717074 *Jun 7, 1995Feb 10, 1998The Rockefeller UniversityMacrophage-derived inflammatory mediator (MIP-2)US5723120 *Jun 7, 1995Mar 3, 1998Chiron CorporationMethod of treating an IL-6 related disease with interleukin-6 receptor antagonistsUS5733742 *Jun 3, 1994Mar 31, 1998Therapeutic Antibodies Inc.Production of antibody fragments from whole bloodUS5741484 *Jun 7, 1995Apr 21, 1998The Rockefeller UniversityMacrophage-derived inflammatory mediator (MIP-1α and MIP-1β)US5760186 *Jun 7, 1995Jun 2, 1998The Rockefeller UniversityAntibody to macrophage-derived inflammatory mediator (MIP-1α and MIP-1β)US5817763 *Jun 7, 1995Oct 6, 1998The Rockefeller UniversityMacrophage-derived inflammatory mediator (MIP-1α and MIP-1β)US5844097 *Jun 7, 1995Dec 1, 1998Monoclonetics International, Inc.Methods for the diagnosis of peripheral nerve damageUS5858688 *Jun 7, 1995Jan 12, 1999Chiron CorporationGro genes, proteins, and uses thereofUS5863535 *Jun 7, 1995Jan 26, 1999The Rockefeller UniversityMacrophage-derived inflammatory mediator (MIP-1α and MIP-1β)US5919452 *Feb 4, 1994Jul 6, 1999New York UniversityMethods of treating TNFα-mediated disease using chimeric anti-TNF antibodiesUS5942222 *Jun 7, 1995Aug 24, 1999The Rockefeller UniversityMethods of treating granulocyte-macrophage progenitor cell-derived blood cell dysfunctionUS5989836 *Jun 7, 1995Nov 23, 1999The Rockefeller UniversityMethod for measuring the binding sites for macrophage-derived inflammatory mediator (MIP-1α and MIP-1β)US5994060 *Jun 7, 1995Nov 30, 1999Chiron CorporationGro genes, proteins, and uses thereofUS6019969 *Jun 7, 1995Feb 1, 2000The Rockefeller UniversityComposition comprising antibody to macrophage-derived inflammatory mediator (MIP-α 1 and MIP-1β)US6063764 *Jun 7, 1995May 16, 2000Washington University & Chiron Corp.Method for using lipoprotein associated coagulation inhibitor to treat sepsisUS6103234 *Jun 7, 1995Aug 15, 2000The Rockefeller UniversityComposition comprising an antibody to macrophage-derived inflammatory mediator (MIP-2)US6193969Jun 3, 1994Feb 27, 2001Protherics Inc.Antibody fragments in therapyUS6277969Aug 12, 1998Aug 21, 2001New York UniversityAnti-TNF antibodies and peptides of human tumor necrosis factorUS6284471Feb 4, 1994Sep 4, 2001New York University Medical CenterAnti-TNFa antibodies and assays employing anti-TNFa antibodiesUS6291210 *Jul 11, 1997Sep 18, 2001Asahi Kasei Kabushiki KaishaDifferentiation inhibitorUS6309640Jun 7, 1995Oct 30, 2001The Rockefeller UniversityLipoprotein lipase suppression by endotoxin-induced mediator (shock assay)US6419927Nov 28, 1994Jul 16, 2002Anthony CeramiMethod for reducing adverse effects of a human 70kDa mediator which results from endotoxin stimulation of macrophagesUS6638741May 16, 2001Oct 28, 2003Asahi Kasei Kabushiki KaishaDifferentiation-suppressive polypeptide serrate-2US6652771Feb 12, 2002Nov 25, 2003Ronald M. CarnPhase change material blend, method for making, and devices using sameUS6790444Jan 8, 2001Sep 14, 2004New York University Medical CenterAnti-TNF antibodies and peptides of human necrosis factorUS6835823Jan 8, 2001Dec 28, 2004New York UniversityAnti-TNF antibodies and peptides of human tumor necrosis factorUS6991791Jan 18, 2001Jan 31, 2006New York University School Of MedicineAnti-TNF antibodies and peptides of human tumor necrosis factorUS7070775Jul 18, 2002Jul 4, 2006New York UniversityRecombinant A2-specific TNFα specific antibodiesUS7101674Jul 2, 2001Sep 5, 2006New York UniversityAnti-idiotypic anti-TNF antibodies and related immunoassay methodsUS7101978Jan 8, 2003Sep 5, 2006Applied Molecular EvolutionTNF-α binding moleculesUS7128907Mar 4, 2003Oct 31, 2006Centocor, Inc.Methods of treating crohn's disease with anti-TNF antibodiesUS7128908Jul 12, 2005Oct 31, 2006Centocor, Inc.Methods for treating systemic lupus erythematosus using anti-TNF antibodies and fragments thereofUS7135178Jun 20, 2002Nov 14, 2006Centocor, Inc.Methods of treating disseminated intravascular coagulation using anti-TNF antibodiesUS7135179Jul 13, 2005Nov 14, 2006Centocor, Inc.Methods for treating sarcoidosis using anti-TNF antibodies and fragments thereofUS7138118Dec 8, 2005Nov 21, 2006Centocor, Inc.Methods of treating rheumatoid arthritis with anti-TNF antibodiesUS7138276Aug 16, 2002Nov 21, 2006Asahi Kasei Kabushiki KaishaDifferentiation-suppressive polypeptide serrate-2 and methods of useUS7160542Jun 29, 2005Jan 9, 2007New York UniversityMethod of treating psoriasis using human anti-TNF antibodies and fragmentsUS7160543Dec 8, 2005Jan 9, 2007New York UniversityMethods of inhibiting TNF-α in patients with Crohn's diseaseUS7160995Jul 22, 2002Jan 9, 2007New York UniversityDNA encoding anti-TNF antibodies and peptidesUS7166284Feb 21, 2003Jan 23, 2007New York UniversityMethods of treating joint inflammation with anti-TNF antibodiesUS7169386Jan 10, 2002Jan 30, 2007New York UniversityMethods of treating inflammation associated with viral infection with anti-TNF antibodiesUS7169388Sep 30, 2004Jan 30, 2007New York UniversityMethods of inhibiting TNFα in patients with cancerUS7179466Jun 28, 2002Feb 20, 2007New York UniversityMethods of treating rheumatoid arthritis by multiple administration of anti-TNF antibodiesUS7179893Apr 7, 2006Feb 20, 2007New York UniversityRecombinant anti-TNF-α antibodiesUS7192584Aug 10, 2001Mar 20, 2007Centocor, Inc.Methods of treating psoriasis with anti-TNF antibodiesUS7204985Feb 21, 2003Apr 17, 2007Centocor, Inc.Methods of treating disseminated intravascular coagulation by multiple administration of anti-TNF antibodiesUS7214376Dec 7, 2001May 8, 2007New York UniversityMethods of inhibiting TNFα in patients with neoplastic diseaseUS7223396Dec 12, 2002May 29, 2007Centocor, Inc.Methods of treatment of fistulas in Crohn's disease with anti-TNF antibodiesUS7226593Jan 10, 2002Jun 5, 2007Centocor, Inc.Methods of treating cachexia with chimeric anti-TNF antibodiesUS7227003Jun 2, 2005Jun 5, 2007New York UniversityAnti-TNF antibody fragmentsUS7250165Aug 1, 2001Jul 31, 2007Centocor, Inc.Anti-TNF antibodies, compositions, methods and usesUS7252823Feb 6, 2004Aug 7, 2007Centocor, Inc.Recombinant A2-specific TNFα-specific antibodiesUS7276239Dec 20, 2005Oct 2, 2007Centocor, Inc.Recombinant A2-specific TNFα-specific antibodiesUS7285269Dec 2, 2003Oct 23, 2007Amgen Fremont, Inc.Antibodies directed to tumor necrosis factorUS7335358Dec 4, 2006Feb 26, 2008Centocor, Inc.Methods of treating psoriasis with anti-TNF antibodiesUS7374761Aug 8, 2007May 20, 2008Centocor, Inc.Recombinant A2-specific TNFα-specific antibodiesUS7404955Aug 2, 2005Jul 29, 2008Centocor, Inc.Methods of inhibiting or neutralizing TNFα in patients with tissue injuryUS7416729Jun 18, 2007Aug 26, 2008Centocor, Inc.Methods of treating rheumatoid arthritis with anti-TNF antibodiesUS7425330Oct 16, 2006Sep 16, 2008Centocor, Inc.Methods of inhibiting TNFα activity in the blood of a patientUS7435799Jan 8, 2004Oct 14, 2008Applied Molecular EvolutionTNF-α binding moleculesUS7517963Jan 5, 2006Apr 14, 2009Arana Therapeutics LimitedTumour necrosis factor binding ligandsUS7521206Jul 13, 2005Apr 21, 2009Centocor, Inc.Anti-TNF antibodies, compositions, methods and usesUS7528237Apr 19, 2007May 5, 2009Arana Therapeutics LimitedTumour necrosis factor binding ligandsUS7544782Feb 23, 2006Jun 9, 2009Arana Therapeutics LimitedTumour necrosis factor binding ligandsUS7553641Jun 7, 2007Jun 30, 2009Arana Therapeutics LimitedTumour necrosis factor binding ligandsUS7605233Jun 11, 2007Oct 20, 2009Arana Therapeutics LimitedTumour necrosis factor binding ligandsUS7662774Jul 15, 2004Feb 16, 2010Novartis Vaccines And Diagnostics, Inc.Method for using lipoprotein associated coagulation inhibitor to treat sepsisUS7674769Oct 15, 2002Mar 9, 2010Novartis Vaccines And Diagnostics, Inc.Treatment of severe pneumonia by administration of tissue factor pathway inhibitor (TFPI)US7691378Jul 30, 2004Apr 6, 2010Centocor, Inc.Anti-TNF antibodies, compositions, methods and usesUS7744885Dec 7, 2007Jun 29, 2010Centocor, Inc.Methods of treating vascular inflammatory pathology using anti-TNF antibodies and fragments thereofUS7815909Nov 13, 2008Oct 19, 2010Centocor, Inc.Anti-TNF antibodies, compositions, methods and usesUS7820169Nov 11, 2008Oct 26, 2010Centocor, Inc.Anti-TNF antibodies, compositions, methods and usesUS8101178Oct 22, 2007Jan 24, 2012Amgen Fremont Inc.Antibodies directed to tumor necrosis factor and uses thereofUS8241899Nov 14, 2008Aug 14, 2012Centocor, Inc.Anti-TNF antibodies, compositions, methods and usesUS8415291Oct 27, 2009Apr 9, 2013Centocor Ortho Biotech Inc.Anti-TNF alpha fibronectin type III domain based scaffold compositions, methods and usesUS8603778Jul 12, 2012Dec 10, 2013Janssen Biotech, Inc.Anti-TNF antibodies, compositions, methods and usesUS8617894Mar 18, 2013Dec 31, 2013Janssen Biotech, Inc.Anti-TNF alpha fibronectin type III domain based scaffold compositions, methods and usesUS8741359Jun 28, 2012Jun 3, 2014Basf Beauty Care Solutions France S.A.S.Method for testing a substance which is potentially active in the field of lipolysis and its mainly cosmetic useUS9321836Feb 18, 2014Apr 26, 2016Janssen Biotech, Inc.Anti-TNF antibodies, compositions, methods and usesUS20010027249 *Jan 8, 2001Oct 4, 2001Centocor, Inc.,Anti-TNF antibodies and peptides of human tumor necrosis factorUS20020022720 *Aug 10, 2001Feb 21, 2002New York University Medical CenterAnti-TNF antibodies and peptides of human tumor necrosis factorUS20020106372 *Jan 18, 2001Aug 8, 2002Centocor, Inc.Anti-TNF antibodies and peptides of human tumor necrosis factorUS20020114805 *Dec 7, 2001Aug 22, 2002New York University Medical CenterMethods of treating myelodysplastic syndrome with anti-TNF antibodiesUS20020141996 *Jan 10, 2002Oct 3, 2002New York University Medical Center and Centocor, Inc.Methods of treating infections with chimeric anti-TNF antibodiesUS20020146419 *Jan 10, 2002Oct 10, 2002New York University Medical CenterMethods of treating ankylosis with chimeric anti-TNF antibodiesUS20030022368 *Aug 16, 2002Jan 30, 2003Asahi Kasei Kogyo Kabushiki KaishaDifferentiation-suppressive polypeptideUS20030032781 *Aug 16, 2002Feb 13, 2003Asahi Kasei Kogyo Kabushiki KaishaDifferentiation-suppressive polypeptideUS20030049725 *Aug 1, 2001Mar 13, 2003George HeavnerAnti-TNF antibodies, compositions, methods and usesUS20030054004 *Jan 10, 2002Mar 20, 2003New York University Medical CenterMethods of treating cachexia with chimeric anti-TNF antibodiesUS20030079600 *Oct 4, 2002May 1, 2003Agm - Academia De Ginastica Movel Ltda.Arrangement of a rythmic apparatus with a vehicle sound apparatus, rhythmic accompaniment method and electronic transducerUS20030086949 *Jun 25, 2001May 8, 2003ColeticaMethod for testing a substance which is potentially active in the field of lipolysis and its mainly cosmetic useUS20030133935 *Jul 29, 2002Jul 17, 2003New York UniversityMethods of treating lung pathologies with chimeric anti-TNF antibodiesUS20030135029 *Dec 16, 2002Jul 17, 2003Rathjen Deborah AnnTumour necrosis factor binding ligandsUS20030139339 *Oct 15, 2002Jul 24, 2003Abla CreaseyTreatment of severe pneumonia by administration of tissue factor pathway inhibitor ( TFPI)US20030139340 *Feb 4, 2003Jul 24, 2003Abla CreaseyTreatment of sepsis by low dose administration of tissue factor pathway inhibitor (TFPI)US20030139577 *Oct 3, 2002Jul 24, 2003Rathjen Deborah AnnTumour necrosis factor binding ligandsUS20030144484 *Jul 18, 2002Jul 31, 2003New York UniversityHuman anti-TNF antibodies and peptidesUS20030147891 *Aug 23, 2002Aug 7, 2003Centocor, Inc.Anti-TNF antibodies and peptides of human tumor necrosis factorUS20030162948 *Oct 3, 2002Aug 28, 2003Rathjen Deborah AnnTumour necrosis factor binding ligandsUS20030166874 *Jan 14, 2003Sep 4, 2003Rathjen Deborah AnnTumour necrosis factor peptide binding antibodiesUS20030170204 *Dec 20, 2002Sep 11, 2003Rathjen Deborah AnnTumour necrosis factor binding ligandsUS20030171292 *Feb 19, 2003Sep 11, 2003Creasey Abla A.Method for using lipoprotein associated coagulation inhibitor to treat sepsisUS20030171553 *Jan 14, 2003Sep 11, 2003Rathjen Deborah AnnTumour necrosis factor binding ligandsUS20030171554 *Jan 15, 2003Sep 11, 2003Rathjen Deborah AnnTumour necrosis factor peptide binding antibodiesUS20030171555 *Jan 15, 2003Sep 11, 2003Rathjen Deborah A.Tumour necrosis factor peptide binding antibodiesUS20030175275 *Jun 28, 2002Sep 18, 2003New York UniversityMethods of treatment by multiple administration of chimeric anti-TNF antibodiesUS20030175837 *Jul 2, 2001Sep 18, 2003New York University Medical CenterAnti-TNF antibodies and peptides of human tumor necrosis factorUS20030176676 *Jun 20, 2002Sep 18, 2003New York UniversityMethods of treating vascular inflammatory pathologies using chimeric anti-TNF antibodiesUS20030180299 *Jun 28, 2002Sep 25, 2003New York UniversityTreatment of heart pathology with chimeric anti-TNF antibodiesUS20030181695 *Feb 21, 2003Sep 25, 2003New York UniversityMethods of treating vascular inflammatory pathology by multiple administration of chimeric anti-TNF antibodiesUS20030187231 *Jul 22, 2002Oct 2, 2003New York UniversityHumanized anti-TNF antibodies and peptidesUS20030194402 *Dec 12, 2002Oct 16, 2003New York UniversityMethods of sustained treatment of fistulas in crohn's disease with chimeric anti-TNF antibodiesUS20030198634 *Feb 21, 2003Oct 23, 2003New York UniversityMethods of treating joint inflammation with chimeric anti-TNF antibodiesUS20030199678 *Dec 16, 2002Oct 23, 2003Rathjen Deborah AnnTumour necrosis factor binding ligandsUS20030204066 *Feb 21, 2003Oct 30, 2003New York UniversityMethods of treating psoriatic arthritis with chimeric anti-TNF antibodiesUS20030208047 *Jan 14, 2003Nov 6, 2003Rathjen Deborah AnnTumour necrosis factor peptide binding antibodiesUS20030208049 *Dec 20, 2002Nov 6, 2003Rathjen Deborah AnnTumour necrosis factor binding ligandsUS20030216552 *Jan 14, 2003Nov 20, 2003Rathjen Deborah AnnTumour necrosis factor peptide binding antibodiesUS20030225254 *Feb 7, 2003Dec 4, 2003Rathjen Deborah AnnTumour necrosis factor binding ligandsUS20030232970 *Dec 16, 2002Dec 18, 2003Rathjen Deborah AnnTumour necrosis factor binding ligandsUS20030232971 *Jun 2, 2003Dec 18, 2003Rathjen Deborah AnnTumour necrosis factor binding ligandsUS20040002588 *Dec 20, 2002Jan 1, 2004Rathjen Deborah AnnTumour necrosis factor binding ligandsUS20040002589 *Jan 14, 2003Jan 1, 2004Rathjen Deborah AnnTumour necrosis factor peptide binding antibodiesUS20040002590 *Jan 15, 2003Jan 1, 2004Rathjen Deborah AnnTumour necrosis factor peptide binding antibodiesUS20040092721 *Jan 15, 2003May 13, 2004Rathjen Deborah AnnTumour necrosis factor peptide binding antibodiesUS20040115200 *Sep 19, 2003Jun 17, 2004New York UniversityMethods of treating neurodegenerative inflammation with chimeric anti-TNF antibodiesUS20040120952 *Aug 8, 2003Jun 24, 2004Centocor, IncAnti-TNF antibodies and peptides of human tumor necrosis factorUS20040131612 *Jan 8, 2003Jul 8, 2004Watkins Jeffry D.TNF-alpha binding moleculesUS20040138427 *Feb 6, 2004Jul 15, 2004Centocor, Inc.Anti-TNF antibodies and peptides of human tumor necrosis factorUS20040214993 *Oct 3, 2002Oct 28, 2004Deborah RathjenTumour necrosis factor binding ligandsUS20050037008 *Sep 30, 2004Feb 17, 2005Centocor, Inc.Methods of treating carcinoma using anti-TNF antibodies and fragments thereofUS20050049402 *Dec 2, 2003Mar 3, 2005Babcook John S.Antibodies directed to tumor necrosis factor and uses thereofUS20050074454 *Sep 30, 2004Apr 7, 2005Centocor, Inc.Methods of treating carcinoma using anti-TNF antibodies and peptidesUS20050181993 *Jul 15, 2004Aug 18, 2005Creasey Abla A.Method for using lipoprotein associated coagulation inhibitor to treat sepsisUS20050249735 *Dec 13, 2004Nov 10, 2005Centocor, Inc.Methods of treating ankylosing spondylitis using anti-TNF antibodies and peptides of human tumor necrosis factorUS20050255104 *Feb 7, 2005Nov 17, 2005Centocor, Inc.Methods of treating psoriasis using anti-TNF receptor fusion proteinsUS20050260201 *Feb 7, 2005Nov 24, 2005Centocor, Inc.Methods of treating rheumatoid arthritis using anti-TNF receptor fusion proteinsUS20060013816 *Jun 29, 2005Jan 19, 2006Centocor, Inc.Method of treating psoriasis using human anti-TNF antibodies and fragmentsUS20060018907 *Jul 14, 2005Jan 26, 2006Centocor, Inc.Anti-TNF antibodies and peptides of human tumor necrosis factorUS20060024310 *Aug 2, 2005Feb 2, 2006Centocor, Inc.Methods of treating TNFalpha-mediated tissue injury using anti-TNF antibodies and peptidesUS20060121037 *Dec 8, 2005Jun 8, 2006Junming LeAnti-TNF antibodies and peptides of human tumor necrosis factorUS20060140949 *Dec 20, 2005Jun 29, 2006Junming LeHuman anti-TNF antibodies and peptidesUS20060140951 *Feb 22, 2006Jun 29, 2006Rathjen Deborah ATumour necrosis factor binding ligandsUS20060159677 *Mar 7, 2006Jul 20, 2006Peptech LimitedTumour necrosis factor peptide binding antibodiesUS20060182746 *Jan 5, 2006Aug 17, 2006Rathjen Deborah ATumour necrosis factor binding ligandsUS20060204499 *May 8, 2006Sep 14, 2006Peptech LimitedTumour necrosis factor binding ligandsUS20060222646 *Mar 2, 2006Oct 5, 2006George TreacyAnti-TNFalpha antibodies in therapy of asthmaUS20060233802 *Jun 6, 2006Oct 19, 2006Peptech LimitedTumour necrosis factor binding ligandsUS20060240017 *Apr 7, 2006Oct 26, 2006Junming LeHuman anti-TNF antibodies and peptidesUS20060269549 *Jan 8, 2004Nov 30, 2006Watkins Jeffry DTnf-alpha binding moleculesUS20060280742 *Dec 8, 2005Dec 14, 2006Junming LeMethods of inhibiting tnf-alpha in patients with crohn's diseaseUS20070009524 *Jan 10, 2002Jan 11, 2007New York University Medical CenterMethods of treating inflammation associated with viral infection with anti-tnf antibodiesUS20070077248 *Feb 23, 2006Apr 5, 2007Peptech LimitedTumour necrosis factor binding ligandsUS20070141057 *Dec 4, 2006Jun 21, 2007Junming LeAnti-TNF antibodies and peptides of human tumor necrosis factorUS20070287177 *Jun 7, 2007Dec 13, 2007Rathjen Deborah ATumour necrosis factor binding ligandsUS20080003228 *Jun 18, 2007Jan 3, 2008Junming LeMethods of treating rheumatoid arthritis with anti-tnf antibodiesUS20080286279 *Mar 17, 2005Nov 20, 2008Chiron CorporationTreatment of Severe Community-Acquired Pneumonia by Administration of Tissue Factor Pathway Inhibitor (Tfpi)US20090022718 *Dec 7, 2007Jan 22, 2009Centocor, Inc.Methods of treating a blood pathology using anti-TNF antibodies and fragments thereofUS20090038182 *Aug 9, 2007Feb 12, 2009Lans Maris JFootwear with built-in scaleUS20090081234 *Nov 20, 2008Mar 26, 2009George HeavnerAnti-tnf antibodies, compositions, methods and uses for treatment of depression and related conditionsUS20090081241 *Nov 14, 2008Mar 26, 2009George HeavnerAnti-TNF Antibodies, Compositions, Methods and UsesUS20090252743 *Nov 11, 2008Oct 8, 2009George HeavnerAnti-TNF Antibodies, Compositions, Methods and UsesUS20100144601 *Oct 27, 2009Jun 10, 2010Steven JacobsAnti-TNF Alpha Fibronectin Type III Domain Based Scaffold Compositions, Methods and UsesUS20110195063 *Sep 17, 2010Aug 11, 2011Centocor, Inc.Methods of Treating Ankylosing Spondylitis Using Anti-TNF Antibodies and Peptides of Human Tumor Necrosis FactorUS20160312226 *Dec 18, 2014Oct 27, 2016University Of DelawareReduction of lipase activity in product formulationsDE10131188A1 *Jun 28, 2001Dec 19, 2002Coletica S AScreening method for identifying inhibitors of lipoprotein lipase, useful in pharmaceuticals and cosmetics, particularly for treatment of fatty deposits in the skinDE10131188B4 *Jun 28, 2001Jun 16, 2005Coletica, S.A.Screening method for identifying inhibitors of lipoprotein lipase, useful in pharmaceuticals and cosmetics, particularly for treatment of fatty deposits in the skinEP0763543A2Sep 1, 1989Mar 19, 1997The Rockefeller UniversityA method for preparing an inflammatory cytokine (MIP-2) and diagnostic and therapeutic applications for the cytokine or its antibody* Cited by examinerClassifications U.S. Classification435/5, 530/388.24, 435/70.4, 435/7.23, 435/188, 435/7.8, 435/198, 436/547, 435/7.32, 435/810, 435/4, 530/350, 435/975, 435/7.21, 530/388.2, 435/29, 435/18, 435/19, 435/7.9, 435/7.22International ClassificationC07K14/47, A61K39/00, C07K16/24, C12P1/00, G01N33/53, A61K38/00, C07K16/38, C07K14/52, C12N5/0789Cooperative ClassificationY10S435/975, Y10S435/81, C12P1/00, G01N33/53, C07K16/24, C07K14/4703, G01N2400/40, A61K39/00, G01N2333/52, C12N2501/21, C07K16/38, C12N2501/22, C07K16/241, C12N5/0647, C07K14/523, A61K38/00European ClassificationC12P1/00, C07K16/24, C07K16/38, G01N33/53, C07K14/52A2, C07K16/24B, C12N5/06B11P, C07K14/47A1ALegal EventsDateCodeEventDescriptionSep 7, 1982ASAssignmentOwner name: ROCKERFELLER UNIVERSITY, 1230 YORK AVE., NEW YORKFree format text: ASSIGNMENT OF ASSIGNORS INTEREST.;ASSIGNORS:CERAMI, ANTHONY;KAWAKAMI, MASANOBU;REEL/FRAME:004045/0180Effective date: 19820829Owner name: ROCKERFELLER UNIVERSITY, A CORP. OF N.Y., NEW YORKFree format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:CERAMI, ANTHONY;KAWAKAMI, MASANOBU;REEL/FRAME:004045/0180Effective date: 19820829Nov 20, 1989FPAYFee paymentYear of fee payment: 4Dec 20, 1993FPAYFee paymentYear of fee payment: 8Nov 13, 1997FPAYFee paymentYear of fee payment: 12RotateOriginal ImageGoogle Home - Sitemap - USPTO Bulk Downloads - Privacy Policy - Terms of Service - About Google Patents - Send FeedbackData provided by IFI CLAIMS Patent Services